Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
M3 ( (JP:2413) ) just unveiled an update.
M3, Inc. reported a significant increase in revenue for the three months ended June 30, 2025, with a 34.2% year-on-year rise to 86,200 million yen. Despite the revenue growth, the company’s total comprehensive income decreased by 46.2% compared to the previous year. The financial results indicate a strong revenue performance, but the decline in comprehensive income may impact stakeholder confidence. The company has not announced any changes to its dividend forecasts, and the financial outlook for the fiscal year ending March 31, 2026, remains unchanged.
The most recent analyst rating on (JP:2413) stock is a Buy with a Yen3300.00 price target. To see the full list of analyst forecasts on M3 stock, see the JP:2413 Stock Forecast page.
More about M3
M3, Inc. operates in the healthcare industry, primarily focusing on providing medical information services. The company is listed on the Tokyo Stock Exchange and is known for its digital platforms that connect healthcare professionals with pharmaceutical companies and medical institutions.
Average Trading Volume: 3,581,566
Technical Sentiment Signal: Hold
Current Market Cap: Yen1283.4B
Find detailed analytics on 2413 stock on TipRanks’ Stock Analysis page.